Summary
This prediction ended on 28.06.22 with a price of €59.96. With a performance of 1.16%, the SELL prediction by Mori8 for Bayer AG was trending in the wrong direction Mori8 has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bayer AG | 4.271% | 4.271% | 67.241% | -31.492% |
| iShares Core DAX® | -0.975% | -4.716% | 4.787% | 53.022% |
| iShares Nasdaq 100 | 1.163% | 1.881% | 20.234% | 95.411% |
| iShares Nikkei 225® | -1.593% | -5.385% | 31.353% | 54.646% |
| iShares S&P 500 | -0.278% | 0.327% | 13.911% | 66.550% |
Comments by Mori8 for this prediction
In the thread Bayer AG diskutieren
Supreme Court lehnt weiteren Glyphosat-Berufungsantrag von Bayer ab
WASHINGTON (dpa-AFX) - Der Bayer -Konzern ist im Dauer-Rechtsstreit um angebliche Glyphosat-Krebsrisiken mit einem weiteren Berufungsantrag beim obersten US-Gericht abgeblitzt. Der US Supreme Court lehnte es am Montag in Washington ab, ein Urteil zugunsten der Kläger Alva und Alberta Pilliod zu überprüfen. Sie machen den glyphosathaltigen Unkrautvernichter Roundup des 2018 von Bayer übernommenen US-Herstellers Monsanto für ihre Krebserkrankungen verantwortlich.
Kursziel gesetzt auf 56,0